• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Adherence to anticoagulant treatment with dabigatran in a real‐world setting
ConclusionIn our clinical practice adherence to the twice‐daily dabigatran regimen was generally good, although 12% of the patients had an inadequate adherence. Routine feedback from the pharmacies could inform the physician to improve the anticoagulant management.This article is protected by copyright. All rights reserved.
Source: Journal of Thrombosis and Haemostasis - April 13, 2013 Category: Hematology Authors: S. Schulman, B. Shortt, M. Robinson, J. W. Eikelboom Tags: Original Article ‐ Clinical Haemostasis and Thrombosis Source Type: research

Cardiovascular mortality due to pulmonary embolism in subjects with renal impairment: patients’ comorbidities are crucial
Abstract we read with great interest the paper by Ocak et al. (1). The authors found that the age‐ and sex‐standardized mortality rate (SMR) for pulmonary embolism (PE) was 12.2 (95% CI 10.2‐14.6) times higher in dialysis patients than in the general population. Such SMR was even higher than that of myocardial infarction (MI) (11.0, 95% CI 10.6‐11.4), stroke (8.4 (95% CI 8.0‐8.8), and other cardiovascular disease (8.3, 95% CI 8.0‐8.5) On the one hand, the association between the different grade of impaired renal function and MI received important confirmation (2), and also a recent study from our group conducte...
Source: Journal of Thrombosis and Haemostasis - April 4, 2013 Category: Hematology Authors: Fabio Fabbian, Francesco Dentali, Walter Ageno, Roberto Manfredini Tags: Letter Rebuttal Source Type: research

Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results. Reply to a rebuttal
We would like to thank Poller et al for his letter and we are happy to reply to their comments. As mentioned by Poller et al many of us participated in the EAA study and are well aware of the results of that study. Time in therapeutic range (TTR) was in fact much higher and bleeding events much lower than those reported in Phase III studies on novel oral anticoagulants (NOAC). However, the aim of our review was to compare the results of the three randomized studies, two of which were double blind double dummy with both the investigators and patients unaware of the type of treatment. © 2013 International Society on Thrombosis and Haemostasis
Source: Journal of Thrombosis and Haemostasis - April 1, 2013 Category: Hematology Authors: V. PENGO, F. MARONGIU, Tags: Letter ‐ Reply to Rebuttal Source Type: research

Remote ischemic preconditioning reduces thrombus formation in the rat
Ischemic preconditioning (IPC) is known to protect tissue from ischemia and has effect both locally[i] and systemically[ii]. Remote IPC (RIPC) induced by limb ischemia provides systemic protection against prolonged ischemia in the target organ. RIPC has been reported to reduce infarct size in patients with ST‐elevation myocardial infarction (STEMI) undergoing primary angioplasty[iii] and is currently evaluated in patients with ischemic stroke undergoing thrombolysis (NCT00975962). © 2013 International Society on Thrombosis and Haemostasis
Source: Journal of Thrombosis and Haemostasis - March 18, 2013 Category: Hematology Authors: DM Røpcke, VE Hjortdal, GE Toft, MO Jensen, SD Kristensen Tags: Letter ‐ to the Editor Source Type: research

MRI artifacts in the ferric chloride thrombus animal model: an alternative solution
This article is protected by copyright. All rights reserved.
Source: Journal of Thrombosis and Haemostasis - June 29, 2013 Category: Hematology Authors: Martijn Wolters, Raf H.M. Hoof, A. Wagenaar, Kim Douma, Marc A.M.J. Zandvoort, Tilman H. Hackeng, Mark J. Post, Walter H. Backes, M. Eline Kooi Tags: Letter ‐ to the Editor Source Type: research

Adherence to anticoagulant treatment with dabigatran in a real‐world setting
ConclusionIn our clinical practice adherence to the twice‐daily dabigatran regimen was generally good, although 12% of the patients had an inadequate adherence. Routine feedback from the pharmacies could inform the physician to improve the anticoagulant management.
Source: Journal of Thrombosis and Haemostasis - July 15, 2013 Category: Hematology Authors: S. Schulman, B. Shortt, M. Robinson, J. W. Eikelboom Tags: Original Article Source Type: research

Coagulation factor XIII Tyr204Phe gene variant and the risk of ischemic stroke
Source: Journal of Thrombosis and Haemostasis - July 15, 2013 Category: Hematology Authors: M. B. Landau, M. S. Renni, M. G. Zalis, N. Spector, T. Gadelha Tags: Letters to the Editor Source Type: research

Munc13‐4‐mediated secretion is essential for infarct progression but not intracranial hemostasis in acute stroke
Source: Journal of Thrombosis and Haemostasis - July 15, 2013 Category: Hematology Authors: D. Stegner, C. Deppermann, P. Kraft, M. Morowski, C. Kleinschnitz, G. Stoll, B. Nieswandt Tags: Letters to the Editor Source Type: research

Type II Antithrombin deficiency caused by a founder mutation Pro73Leu in the Finnish population – clinical picture
ConclusionIn Finland, a population with a strong founder effect, AT type II deficiency is caused predominantly by a single point mutation p.Pro73Leu. The mutation is associated with a significant thrombotic risk. Reduced AT activity caused by this mutation cannot be detected by all available screening methods. This must be taken into account in the choice of laboratory method used for screening.This article is protected by copyright. All rights reserved.
Source: Journal of Thrombosis and Haemostasis - July 1, 2013 Category: Hematology Authors: M Puurunen, P Salo, S Engelbarth, K Javela, M Perola Tags: Original Article ‐ Clinical Haemostasis and Thrombosis Source Type: research

Type II antithrombin deficiency caused by a founder mutation Pro73Leu in the Finnish population: clinical picture
ConclusionIn Finland, a population with a strong founder effect, AT type II deficiency is caused predominantly by a single point mutation, p.Pro73Leu. The mutation is associated with a significant thrombotic risk. Reduced AT activity caused by this mutation cannot be detected by all available screening methods. This must be taken into account in the choice of laboratory method used for screening.
Source: Journal of Thrombosis and Haemostasis - October 10, 2013 Category: Hematology Authors: M. Puurunen, P. Salo, S. Engelbarth, K. Javela, M. Perola Tags: Original Article Source Type: research

The DRY Motif at Work: The P2Y12 Receptor Case
This article is protected by copyright. All rights reserved.
Source: Journal of Thrombosis and Haemostasis - February 1, 2014 Category: Hematology Authors: G. Enrico Rovati, Valérie Capra Tags: Commentary Source Type: research

Report of the Subcommittee on Control of Anticoagulation on the determination of the anticoagulant effects of apixaban: communication from the SSC of the ISTH
This article is protected by copyright. All rights reserved.
Source: Journal of Thrombosis and Haemostasis - March 5, 2014 Category: Hematology Authors: Job Harenberg, Shanshan Du, Christel Weiss, Roland Krämer, Debra Hoppensteadt, Jeanine Walenga, Tags: Recommendations and Guidelines Source Type: research

Associations of Pentraxin 3 with Cardiovascular Disease: The Multi‐Ethnic Study of Atherosclerosis
ConclusionsIn these apparently healthy adults, PTX3 was associated with CVD risk factors, subclinical CVD, CAC and incident coronary heart disease events independent of CRP and CVD risk factors. These results support the hypothesis that PTX3 reflects different aspects of inflammation than CRP and may provide additional insight into the development and progression of atherosclerosis.This article is protected by copyright. All rights reserved.
Source: Journal of Thrombosis and Haemostasis - March 1, 2014 Category: Hematology Authors: Nancy Swords Jenny, Roger S. Blumenthal, Richard A. Kronmal, Jerome I. Rotter, David S. Siscovick, Bruce M. Psaty Tags: Original Article ‐ Vascular Biology Source Type: research

It's not about sex
This article is protected by copyright. All rights reserved.
Source: Journal of Thrombosis and Haemostasis - March 15, 2014 Category: Hematology Authors: M. Greaves Tags: Commentary Source Type: research

Associations of pentraxin 3 with cardiovascular disease: the Multi‐Ethnic Study of Atherosclerosis
ConclusionsIn these apparently healthy adults, PTX3 was associated with CVD risk factors, subclinical CVD, CAC and incident coronary heart disease events independently of CRP and CVD risk factors. These results support the hypothesis that PTX3 reflects different aspects of inflammation than CRP, and may provide additional insights into the development and progression of atherosclerosis.
Source: Journal of Thrombosis and Haemostasis - June 10, 2014 Category: Hematology Authors: N. S. Jenny, R. S. Blumenthal, R. A. Kronmal, J. I. Rotter, D. S. Siscovick, B. M. Psaty Tags: Original Article Source Type: research

Pages: 1  2  3  4  5  6  7  8  9  10